Devalingam Mahalingam
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)

Dr. Devalingam Mahalingam

Hematology | Oncology
Northwestern Medical Group
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
Offers Telehealth
26 Years of Experience
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Northwestern Medical Group
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Devalingam Mahalingam is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Mahalingam has been practicing medicine for over 26 years and is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Colorectal Cancer, and Liver Embolization.

His clinical research consists of co-authoring 94 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles and participated in 2 clinical trials in the study of Cholangiocarcinoma (Bile Duct Cancer).

Graduate Institution
National University Of Ireland Galway, 2000.0
Specialties
Hematology
Oncology
Licenses
Internal Medicine in TX
Board Certifications
American Board Of Internal Medicine - Internal Medicine (Certified)
Fellowships
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine
Hospital Affiliations
Northwestern Memorial Hospital
Palos Community Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

675 N St Clair St Ste 21-100, Galter Pavilion, Chicago, IL 60611
Call: 866-587-4322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Pevonedistat
Study Phase: Phase 2
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: October 27, 2025
Intervention Type: Drug
Study Drug: Adavosertib
Study Phase: Phase 2
Modulation of Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
Modulation of Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
Enrollment Status: Completed
Publish Date: September 04, 2025
Intervention Type: Drug
Study Drugs: Sorafenib, Hydroxychloroquine
Study Phase: Phase 2
A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)
A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Pembrolizumab, Sorafenib Tosylate
Study Phase: Phase 1/Phase 2
A Phase I/Ib, Open-label, Multi-center, Study of KAZ954 as a Single Agent and in Combination With Spartalizumab, NZV930 and NIR178 in Patients With Advanced Solid Tumors
A Phase I/Ib, Open-label, Multi-center, Study of KAZ954 as a Single Agent and in Combination With Spartalizumab, NZV930 and NIR178 in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: May 18, 2025
Intervention Type: Drug
Study Phase: Early Phase 1
A Phase 1, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Patients With Relapsed/Refractory Malignancies
A Phase 1, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Patients With Relapsed/Refractory Malignancies
Enrollment Status: Completed
Publish Date: April 16, 2025
Intervention Type: Drug
Study Phase: Phase 1
Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies
Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Enrollment Status: Completed
Publish Date: July 11, 2024
Intervention Type: Drug
Study Drugs: CPI 613, Gemcitabine, Cisplatin
Study Phase: Phase 1/Phase 2
Modulation of Autophagy: A Clinical Study of Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) Patients (CTMS# 14-2015)
Modulation of Autophagy: A Clinical Study of Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) Patients (CTMS# 14-2015)
Enrollment Status: Completed
Publish Date: January 05, 2024
Intervention Type: Drug
Study Phase: Phase 2
Inhibition of Autophagy in Solid Tumors: A Phase I Pharmacokinetic and Pharmacodynamic Study of Hydroxychloroquine in Combination With the HDAC Inhibitor Vorinostat for the Treatment of Patients With Advanced Solid Tumors With an Expansion Study in Advanced Renal and Colorectal Cancer
Inhibition of Autophagy in Solid Tumors: A Phase I Pharmacokinetic and Pharmacodynamic Study of Hydroxychloroquine in Combination With the HDAC Inhibitor Vorinostat for the Treatment of Patients With Advanced Solid Tumors With an Expansion Study in Advanced Renal and Colorectal Cancer
Enrollment Status: Completed
Publish Date: February 13, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Study of Pembrolizumab in Combination With Pelareorep in Patients With Advanced Pancreatic Adenocarcinoma
A Phase 2 Study of Pembrolizumab in Combination With Pelareorep in Patients With Advanced Pancreatic Adenocarcinoma
Enrollment Status: Terminated
Publish Date: October 05, 2022
Intervention Type: Biological
Study Drugs: Pembrolizumab, Wild-type Reovirus
Study Phase: Phase 2
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Enrollment Status: Completed
Publish Date: May 27, 2022
Intervention Type: Biological
Study Phase: Phase 2
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
Enrollment Status: Completed
Publish Date: December 10, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b Study of Pembrolizumab (KEYTRUDA®) in Combination With REOLYSIN® (Pelareorep) and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
A Phase 1b Study of Pembrolizumab (KEYTRUDA®) in Combination With REOLYSIN® (Pelareorep) and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: September 13, 2018
Intervention Type: Biological, Drug
Study Phase: Phase 1
View 14 Less Clinical Trials

94 Total Publications

First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.
First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.
Journal: Journal of hematology & oncology
Published: July 19, 2025
View All 94 Publications
Similar Doctors
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Aparna Kalyan
Hematology | Oncology
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Aparna Kalyan
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Experience:
21+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Aparna Kalyan is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Kalyan has been practicing medicine for over 21 years and is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Tissue Biopsy, and Liver Embolization.

Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Mary F. Mulcahy
Hematology | Oncology
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Mary F. Mulcahy
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Experience:
33+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mary Mulcahy is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Mulcahy has been practicing medicine for over 33 years and is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Neuroendocrine Tumor, Liver Embolization, and Pancreaticoduodenectomy.

Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Daniel V. Catenacci
Hematology | Oncology
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Daniel V. Catenacci
Hematology | Oncology
5841 S Maryland Ave, 
Chicago, IL 
 (7.4 miles away)
888-824-0200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Catenacci is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Catenacci is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Stomach Cancer, Gastroesophageal Junction Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Colorectal Cancer. Dr. Catenacci is currently accepting new patients.

VIEW MORE CHOLANGIOCARCINOMA (BILE DUCT CANCER) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mahalingam's expertise for a condition
ConditionClose
    • Distinguished
    • Anal Cancer
      Dr. Mahalingam is
      Distinguished
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Cholangiocarcinoma (Bile Duct Cancer)
      Dr. Mahalingam is
      Distinguished
      . Learn about Cholangiocarcinoma (Bile Duct Cancer).
      See more Cholangiocarcinoma (Bile Duct Cancer) experts
    • Colorectal Cancer
      Dr. Mahalingam is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Familial Colorectal Cancer
      Dr. Mahalingam is
      Distinguished
      . Learn about Familial Colorectal Cancer.
      See more Familial Colorectal Cancer experts
    • Familial Pancreatic Cancer
      Dr. Mahalingam is
      Distinguished
      . Learn about Familial Pancreatic Cancer.
      See more Familial Pancreatic Cancer experts
    • Pancreatic Cancer
      Dr. Mahalingam is
      Distinguished
      . Learn about Pancreatic Cancer.
      See more Pancreatic Cancer experts
    • Advanced
    • Fibrolamellar Carcinoma
      Dr. Mahalingam is
      Advanced
      . Learn about Fibrolamellar Carcinoma.
      See more Fibrolamellar Carcinoma experts
    • Gallbladder Adenocarcinoma
      Dr. Mahalingam is
      Advanced
      . Learn about Gallbladder Adenocarcinoma.
      See more Gallbladder Adenocarcinoma experts
    • Gallbladder Cancer
      Dr. Mahalingam is
      Advanced
      . Learn about Gallbladder Cancer.
      See more Gallbladder Cancer experts
    • Liver Cancer
      Dr. Mahalingam is
      Advanced
      . Learn about Liver Cancer.
      See more Liver Cancer experts
    • Lung Cancer
      Dr. Mahalingam is
      Advanced
      . Learn about Lung Cancer.
      See more Lung Cancer experts
    • Lynch Syndrome
      Dr. Mahalingam is
      Advanced
      . Learn about Lynch Syndrome.
      See more Lynch Syndrome experts
    View All 10 Advanced Conditions
    • Experienced
    • Adenoid Cystic Carcinoma
      Dr. Mahalingam is
      Experienced
      . Learn about Adenoid Cystic Carcinoma.
      See more Adenoid Cystic Carcinoma experts
    • Adrenal Cancer
      Dr. Mahalingam is
      Experienced
      . Learn about Adrenal Cancer.
      See more Adrenal Cancer experts
    • Adrenocortical Carcinoma
      Dr. Mahalingam is
      Experienced
      . Learn about Adrenocortical Carcinoma.
      See more Adrenocortical Carcinoma experts
    • Adult Soft Tissue Sarcoma
      Dr. Mahalingam is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Agranulocytosis
      Dr. Mahalingam is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Alveolar Soft Part Sarcoma
      Dr. Mahalingam is
      Experienced
      . Learn about Alveolar Soft Part Sarcoma.
      See more Alveolar Soft Part Sarcoma experts
    View All 64 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.